RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $72,681 | -7.0% | 7,290 | -8.0% | 0.00% | -25.0% |
| Q4 2023 | $78,111 | +28.9% | 7,922 | 0.0% | 0.00% | +33.3% |
| Q3 2023 | $60,603 | +7.5% | 7,922 | +4.9% | 0.00% | 0.0% |
| Q2 2023 | $56,391 | +12.0% | 7,549 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $50,352 | -22.0% | 7,549 | -9.9% | 0.00% | 0.0% |
| Q4 2022 | $64,571 | -27.5% | 8,375 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $89,110 | +30.7% | 8,375 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $68,173 | +23.8% | 8,375 | +8.9% | 0.00% | +50.0% |
| Q1 2022 | $55,053 | -89.5% | 7,689 | -74.8% | 0.00% | -71.4% |
| Q4 2021 | $522,842 | +179.4% | 30,522 | +275.2% | 0.01% | +133.3% |
| Q3 2021 | $187,163 | -23.1% | 8,134 | +22.0% | 0.00% | 0.0% |
| Q2 2021 | $243,346 | – | 6,667 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |